Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Generex Biotechnology Corp GNBTQ

Healthcare Biotechnology
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and... see more

Recent & Breaking News (EXPM:GNBTQ)

Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix

Business Wire January 3, 2019

PURA - Puration 2018 Sales Exceed $1 Million Goal With 2019 Goal Set At $5 Million and NOUV Dividend Coming Sooner Than Planned

GlobeNewswire December 20, 2018

Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen

Business Wire December 20, 2018

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

Business Wire December 14, 2018

Kali-Extracts and Puration Announce First Shipment Of Hemp-Derived CBD Infused Private Label Water For Pharmaceutical Client

GlobeNewswire December 13, 2018

Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing

Business Wire December 13, 2018

Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer

Business Wire December 12, 2018

Generex Provides Stock Market Alert

Business Wire December 10, 2018

Uptick Newswire’s Stock Day Podcast Features Generex Biotechnology Corp.’s CEO to Discuss Recent Acquisitions and Their Value to The Company

GlobeNewswire December 6, 2018

Generex Posts Slides, Script & Recording of Investor Conference Call

Business Wire December 4, 2018

PURA - Puration Patented CBD Extraction Process Highlighted In Generex Shareholder Call

GlobeNewswire December 3, 2018

Generex Announces Acquisition of 100% of Hema Diagnostic Systems, Debt Restructuring & Warrant Deal

Business Wire December 3, 2018

Generex Announces Investor Conference Call-in Details; Management to Provide Update on Initiatives & Strategic Plans

Business Wire November 30, 2018

Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation

Business Wire November 29, 2018

Generex Biotechnology Adds World-Class Leadership to Executive Management Team

Business Wire November 28, 2018

Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.

PR Newswire November 28, 2018

Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer

Business Wire November 27, 2018

Generex Announces NuGenerex HydroHealth CBD High Alkaline Health Water As First Target Product In Planned Line Of CBD Therapies

Business Wire November 26, 2018

Generex Provides Stock Market Alert

Business Wire November 21, 2018

Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans

Business Wire November 16, 2018